New data on lecanemab to be presented at CTAD conference BioArctic (Nasdaq: B) announced that partner Eisai will present new data on lecanemab (Leqembi) at the CTAD conference in San Diego, Dec 1–4, 2025.Presentations cover long‑term treatment analyses, estimated time savings over 10 years, safety and pharmacokinetics for a subcutaneous initiation option, effects on soluble Aβ protofibrils, and real‑world registry findings including ALZ‑NET and a Japanese post‑marketing study.

#B #BIOA #BIOAB New data on lecanemab to be presented at CTAD conference

www.stocktitan.net/news/B/new-data-on-lecan...